Researchers announced that Deliver Biosciences has been awarded the Fortis Grant Series 2026, which will provide access to advanced antibody discovery services. This grant aims to accelerate the development of new therapeutic programs targeting serious diseases that are challenging to treat, such as cancer and autoimmune disorders. The unique VHH antibodies, which are smaller and more stable than traditional antibodies, can penetrate dense tissues like solid tumors more effectively, potentially leading to more precise treatments.

This development is significant for anyone interested in healthy aging and longevity. The ability to create targeted therapies could mean better treatment options for conditions that affect older adults, such as certain cancers and neurodegenerative diseases. By improving the effectiveness of treatments, these advancements could enhance muscle strength, memory, and overall health as people age. The grant supports innovative research that could ultimately lead to new medications that address pressing health issues.

The research is still in the early stages, with the grant facilitating access to advanced technologies for organizations that might not otherwise afford them. While this is a promising step towards developing effective therapies, the results are not yet proven in large-scale human trials. Deliver Biosciences is working on therapies that could enter clinical trials soon, particularly in the areas of CAR-T therapy and gene therapy, which hold great potential for treating various diseases.

For those interested in the future of health treatments, staying informed about advancements in biotechnology and new therapies can be beneficial. Engaging with updates from organizations like Deliver Biosciences may provide insights into potential treatments that could improve health outcomes as we age.

Source: globenewswire.com